Drug used to treat breast, colorectal cancers London - Arab Today A drug used to treat advanced breast and colorectal cancers has been linked to sometimes fatal skin reactions in patients, its Swiss manufacturer and Canadian health officials said. Xeloda, which treats advanced cancer after complete surgical removal, can cause "severe skin reactions," Health Canada said in a statement. It said patients had reported severe skin reactions, such as the life-threatening skin condition known as Stevens'Johnson Syndrome or toxic epidermal necrolysis. The signs and symptoms of this hypersensitivity include flu-like symptoms, fever, itchy skin, mouth sores, as well as painful, red or purplish skin rash that spreads and blisters, causing the top of the skin to shed, along with eye burning, itching and discharge. Health Canada urged patients using Xeloda to contact their physician "immediately" after experiencing any of those signs or symptoms, so that they may report these adverse reactions to Roche or Health Canada. Following requests from Canadian health authorities, Hoffmann-La Roche said it will be working with Health Canada to update the drug's prescribing information document. It has sent a letter to healthcare professionals warning of the "risk of severe cutaneous reactions associated with the use of Xeloda," though it stressed that those cases were "very rare." Source: AFP
GMT 12:06 2018 Thursday ,13 December
Blue light in smartphones linked to blindness and some cancersGMT 11:56 2018 Friday ,30 November
Congo Ebola outbreak becomes second-worst in history, IRC saysGMT 17:52 2018 Sunday ,25 November
Russian medical team provides services to citizen in Talbiseh town in HomsGMT 11:28 2018 Thursday ,15 November
Cameroon strives to curb maternal and infant mortality in restive Anglophone regionsGMT 15:36 2018 Tuesday ,30 October
China’s invitation to pool efforts in finding cure for cancer and AIDSGMT 17:19 2018 Monday ,22 October
New campaign launched in Cairo to raise awareness of migrainesGMT 13:36 2018 Friday ,19 October
Egypt elected as member in joint coordination council of WHO programmeGMT 11:51 2018 Wednesday ,17 October
Syria, ICRC sign two MoUs on treatment diabetes and LeishmaniasisMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor